Browsing: Pharma

Brazil’s health regulator, Anvisa, approved the registration of five new semaglutide injection pens on Wednesday (29). The decision marks the entry of Brazilian pharmaceutical company Hypera, Switzerland’s Sandoz, and India’s Sun Pharma into the market for the molecule used in weight-loss pens made by Denmark’s Novo Nordisk, the manufacturer of Ozempic and Wegovy. Brazil has…

PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, announces that a share purchase agreement was made between entities controlled by Dorte X. Gram, Chairman of the Board of PILA PHARMA AB

AI Generated by Fortune India USV Pharma deal gives Wellbeing Nutrition the runway for ₹1,000 crore ambitionJuly 27, 2026, 21:21 IST Loading AI Hub… Disclaimer : Certain content on this page, including summaries, timelines, FAQs, glossaries, highlights, insights, and other supplementary informational features, maybe generated or assisted by artificial intelligence tools. While reasonable efforts are…

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments. 

Novo Nordisk said Eli Lilly’s ads uses outdated research and leave out important information, which could mislead consumers

A woman holds an Ozempic needle shot pen in Warsaw, Poland in November 2023. See all topics London — 

Poolbeg Pharma (LSE:POLB) has raised £3.5 million through a placing of 58.3 million new ordinary shares at 6 pence each, representing a 16% discount to the previous closing price. Executive Chair Cathal Friel participated in the fundraising with a £250,000 investment

The U.S. obesity rate dropped as use of GLP-1 weight loss drugs surged.A Gallup survey finds the use of GLP-1 weight loss drugs at a new high even as the U.S. obesity rate shows a ‘meaningful’ decline. (U.S. News and World Report)

Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment